0
Telix Pharmaceuticals Limited Banner Image

Telix Pharmaceuticals Limited has reached its limit for free report views

Work for Telix Pharmaceuticals Limited? Upgrade Your Profile and unlock all your responsibility reports.

Telix Pharmaceuticals Limited

  • Ticker TLX
    Exchange ASX More
  • Industry Biotechnology More
  • Sector Healthcare More
Telix Pharmaceuticals Limited Logo Image
  • 51-200 Employees
  • Based in North Melbourne, Australia
Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation products for unmet needs in cancer care in Australia, Belgium, Japan, and the United States. The company focuses on developing diagnostic and therapeutic products using molecularly targeted radiation (MTR). Its lead products include TLX250, which is in Phase II clinical trials for the diagnosisMore and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in pre-Phase 3 development for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX591-CDx that is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; and TLX101, which is in Phase I/II clinical trial for the treatment of glioblastoma (brain cancer). The company has a strategic collaboration with RefleXion Medical for the treatment of high-risk cancers; a strategic license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for developing a portfolio of MTR products; and scientific and clinical research collaboration with Mauna Kea Technologies. In addition, it has a collaboration with Kanazawa University to commence a Phase I trial of prostate cancer imaging product TLX591-CDxin Japan; and strategic collaboration agreement with Lightpoint Medical, Ltd. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
REPORT RATINGS
5.0 / 5.0 (2)

Telix Pharmaceuticals Limited reports have an aggregate usefulness score of 5.0 based on 2 reviews.

Telix Pharmaceuticals Limited

Most Recent Responsibility Report

Telix Pharmaceuticals Limited
MOST RECENT 2023 Sustainability Report

Report Locked. Telix Pharmaceuticals Limited has reached its limit for free report views.

Telix Pharmaceuticals Limited does not currently have any hardcopy reports on ResponsibilityReports.com. Click the button below to request a report when hardcopies become available.

Request Information

Archived Responsibility Reports

Our service enables potential investors to review the most recent and archived Telix Pharmaceuticals Limited Sustainability Report, Telix Pharmaceuticals Limited Corporate Social Responsibility Report, Telix Pharmaceuticals Limited CSR Report, Telix Pharmaceuticals Limited Corporate Responsibility, Telix Pharmaceuticals Limited CR Report, Telix Pharmaceuticals Limited Citizenship Report, Telix Pharmaceuticals Limited ESG Report, and Telix Pharmaceuticals Limited Environmental Report online.
Telix Pharmaceuticals Limited Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!